BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 26498952)

  • 1. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: a European HR-NBL1/SIOPEN study.
    Viprey VF; Gregory WM; Corrias MV; Tchirkov A; Swerts K; Vicha A; Dallorso S; Brock P; Luksch R; Valteau-Couanet D; Papadakis V; Laureys G; Pearson AD; Ladenstein R; Burchill SA
    J Clin Oncol; 2014 Apr; 32(10):1074-83. PubMed ID: 24590653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal disease detection in peripheral blood and bone marrow from patients with non-metastatic neuroblastoma.
    Yáñez Y; Grau E; Oltra S; Cañete A; Martínez F; Orellana C; Noguera R; Palanca S; Castel V
    J Cancer Res Clin Oncol; 2011 Aug; 137(8):1263-72. PubMed ID: 21706131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis.
    Träger C; Vernby A; Kullman A; Ora I; Kogner P; Kågedal B
    Int J Cancer; 2008 Dec; 123(12):2849-55. PubMed ID: 18814238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
    Shono K; Tajiri T; Fujii Y; Suita S
    J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
    Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly sensitive assessment of neuroblastoma minimal residual disease in ovarian tissue using RT-qPCR-A strategy for improving the safety of fertility restoration.
    Grèze V; Brugnon F; Chambon F; Halle P; Canis M; Amiot C; Grémeau AS; Pereira B; Yáñez Peralta Y; Tchirkov A; Kanold J
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27734578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two methods for evaluating bone marrow metastasis of neuroblastoma: Reverse transcription-polymerase chain reaction for tyrosine hydroxylase and magnetic resonance imaging.
    Takemoto C; Nishiuchi R; Endo C; Oda M; Seino Y
    Pediatr Int; 2004 Aug; 46(4):387-93. PubMed ID: 15310300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Tyrosine Hydroxylase mRNA Transcripts in Peripheral Blood at Diagnosis in Patients with Neuroblastoma.
    Lee NH; Son MH; Choi YB; Yi E; Lee JW; Yoo KH; Sung KW; Koo HH
    Cancer Res Treat; 2016 Oct; 48(4):1399-1407. PubMed ID: 27034145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma.
    Tchirkov A; Paillard C; Halle P; Bernard F; Bordigoni P; Vago P; Deméocq F; Kanold J
    J Hematother Stem Cell Res; 2003 Aug; 12(4):435-42. PubMed ID: 12965080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection procedures for neuroblastoma cells metastatic to blood and bone marrow: blinded comparison of chromogranin A heminested reverse transcription polymerase chain reaction to tyrosine hydroxylase nested reverse transcription polymerase chain reaction and to anti-GD2 immunocytology.
    Pagani A; Macri L; Faulkner LB; Tintori V; Paoli A; Garaventa A; Bussolati G
    Diagn Mol Pathol; 2002 Jun; 11(2):98-106. PubMed ID: 12045713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
    Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
    Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease outcome may be predicted by molecular detection of minimal residual disease in bone marrow in advanced neuroblastoma: a pilot study.
    Fukuda M; Miyajima Y; Miyashita Y; Horibe K
    J Pediatr Hematol Oncol; 2001 Jan; 23(1):10-3. PubMed ID: 11196262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The doublecortin gene, a new molecular marker to detect minimal residual disease in neuroblastoma.
    Oltra S; Martinez F; Orellana C; Grau E; Fernandez JM; Cañete A; Castel V
    Diagn Mol Pathol; 2005 Mar; 14(1):53-7. PubMed ID: 15714065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
    Corrias MV; Faulkner LB; Pistorio A; Rosanda C; Callea F; Piccolo MS; Scaruffi P; Marchi C; Lacitignola L; Occhino M; Gambini C; Tonini GP; Haupt R; De Bernardi B; Pistoia V; Garaventa A
    Clin Cancer Res; 2004 Dec; 10(23):7978-85. PubMed ID: 15585633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential application of ELAVL4 real-time quantitative reverse transcription-PCR for detection of disseminated neuroblastoma cells.
    Swerts K; De Moerloose B; Dhooge C; Vandesompele J; Hoyoux C; Beiske K; Benoit Y; Laureys G; Philippé J
    Clin Chem; 2006 Mar; 52(3):438-45. PubMed ID: 16384890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.